HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment.

Abstract
Resveratrol is known to improve endothelial function in animals, but little is known about its effect on human subjects. Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors underlying endothelial dysfunction. We hypothesized that the modified resveratrol, Longevinex, improves endothelial function in patients with MetS. Thirty-four patients who had been treated for MetS and lifestyle-related disease were randomly assigned to group A, in which Longevinex was administered for 3 months and then discontinued for 3 months, whereas in the time-matched group B, Longevinex was administered between 3 and 6 months. These 2 groups of patients received similar drugs at baseline for diabetes mellitus, dyslipidemia, or hypertension. Flow-mediated dilatation significantly increased during the administration of Longevinex but decreased to baseline 3 months after the discontinuation of Longevinex in the group A patients. Conversely, in the group B patients, flow-mediated dilatation remained unchanged for the first 3 months without Longevinex but was significantly increased 3 months after the treatment with Longevinex. Longevinex did not significantly affect blood pressure, insulin resistance, the lipid profile or inflammatory markers during 6-month follow-up. These results demonstrate that Longevinex specifically improves endothelial function in subjects with MetS who were receiving standard therapy for lifestyle-related disease.
AuthorsKeisuke Fujitaka, Hajime Otani, Fusakazu Jo, Hiromi Jo, Emiko Nomura, Masayoshi Iwasaki, Mitsushige Nishikawa, Toshiji Iwasaka, Dipak K Das
JournalNutrition research (New York, N.Y.) (Nutr Res) Vol. 31 Issue 11 Pg. 842-7 (Nov 2011) ISSN: 1879-0739 [Electronic] United States
PMID22118755 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Stilbenes
  • Vasodilator Agents
  • Resveratrol
Topics
  • Aged
  • Diabetes Mellitus (drug therapy)
  • Drug Compounding
  • Endothelium, Vascular (physiopathology)
  • Female
  • Humans
  • Hyperlipidemias (complications, drug therapy)
  • Hypertension (complications, drug therapy)
  • Insulin Resistance
  • Life Style
  • Male
  • Metabolic Syndrome (complications, drug therapy, physiopathology)
  • Middle Aged
  • Resveratrol
  • Stilbenes (administration & dosage)
  • Vasodilation
  • Vasodilator Agents (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: